Presentation will highlight data demonstrating the non-sedating effects of tolperisone
| SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurana Pharmaceuticals Inc., a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that data from a Phase 1 clinical study demonstrating the non-sedating effects of tolperisone in a simulated driving performance and cognitive functioning assessment in healthy adult volunteers will be presented at the American College of Emergency Physicians (ACEP) October 1-4, 2018 in San Diego, California. “We look forward to sharing the results of this Phase 1 clinical driving simulation study at this important meeting,” said Craig Thompson, President and Chief Executive Officer of Neurana. “The clinical data we will present at ACEP supports our commitment to advancing the development of tolperisone as a novel treatment for potentially treating acute painful muscle spasms in the United States and Canada.” The ACEP18 presentation by Neurana Pharmaceuticals is as follows: Title: No Evidence of Sedation of Tolperisone Compared to Cyclobenzaprine in a Crossover Driving Simulation Study About Tolperisone Neurana is preparing to commence a Phase 2 dose-ranging clinical study to further demonstrate the safety and efficacy of tolperisone in subjects with acute, painful muscle spasms of the back. About Neurana Pharmaceuticals Contact:
SOURCE Neurana Pharmaceuticals, Inc. |
View original content:
